Insulin-like Growth Factor-binding Protein 7 as a Biomarker of Diastolic Dysfunction and Functional Capacity: Results From the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With Preserved Ejection Fraction (RELAX) Trial
Publication
, Conference
Gandhi, PU; Redfield, MM; Chen, HH; Stevens, SR; Anstrom, KJ; Gaggin, HK; Semigran, MJ; Januzzi, JL
Published in: CIRCULATION
November 10, 2015
Duke Scholars
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
November 10, 2015
Volume
132
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gandhi, P. U., Redfield, M. M., Chen, H. H., Stevens, S. R., Anstrom, K. J., Gaggin, H. K., … Januzzi, J. L. (2015). Insulin-like Growth Factor-binding Protein 7 as a Biomarker of Diastolic Dysfunction and Functional Capacity: Results From the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With Preserved Ejection Fraction (RELAX) Trial. In CIRCULATION (Vol. 132). LIPPINCOTT WILLIAMS & WILKINS.
Gandhi, Parul U., Margaret M. Redfield, Horng H. Chen, Susanna R. Stevens, Kevin J. Anstrom, Hanna K. Gaggin, Marc J. Semigran, and James L. Januzzi. “Insulin-like Growth Factor-binding Protein 7 as a Biomarker of Diastolic Dysfunction and Functional Capacity: Results From the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With Preserved Ejection Fraction (RELAX) Trial.” In CIRCULATION, Vol. 132. LIPPINCOTT WILLIAMS & WILKINS, 2015.
Gandhi PU, Redfield MM, Chen HH, Stevens SR, Anstrom KJ, Gaggin HK, et al. Insulin-like Growth Factor-binding Protein 7 as a Biomarker of Diastolic Dysfunction and Functional Capacity: Results From the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With Preserved Ejection Fraction (RELAX) Trial. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2015.
Gandhi, Parul U., et al. “Insulin-like Growth Factor-binding Protein 7 as a Biomarker of Diastolic Dysfunction and Functional Capacity: Results From the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With Preserved Ejection Fraction (RELAX) Trial.” CIRCULATION, vol. 132, LIPPINCOTT WILLIAMS & WILKINS, 2015.
Gandhi PU, Redfield MM, Chen HH, Stevens SR, Anstrom KJ, Gaggin HK, Semigran MJ, Januzzi JL. Insulin-like Growth Factor-binding Protein 7 as a Biomarker of Diastolic Dysfunction and Functional Capacity: Results From the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With Preserved Ejection Fraction (RELAX) Trial. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2015.
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
November 10, 2015
Volume
132
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology